Loading clinical trials...
Loading clinical trials...
A Phase I, Two-arm, Open-label, Single-center, Dose-escalation Study to Evaluate the Safety, Tolerability and Recommended Dose and Delivery Mode of the Pan-immunotherapy in Subjects With Unresectable/ Metastatic Solid Tumors or Lymphomas
Conditions
Interventions
Manganese Chloride
Anti-PD-1 antibody
+1 more
Locations
1
China
Biotherapeutic Department of Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Start Date
November 1, 2018
Primary Completion Date
December 31, 2019
Completion Date
May 31, 2020
Last Updated
August 28, 2019
NCT05529069
NCT07388563
NCT06337318
NCT06898450
NCT05720117
NCT06263491
Lead Sponsor
Chinese PLA General Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions